Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O75083

UPID:
WDR1_HUMAN

ALTERNATIVE NAMES:
Actin-interacting protein 1; NORI-1

ALTERNATIVE UPACC:
O75083; A8K6E9; A8MPU4; O75313; Q8N6E5; Q9UG05; Q9UG78; Q9UQE0

BACKGROUND:
The WD repeat-containing protein 1, known alternatively as Actin-interacting protein 1 and NORI-1, is integral to several cellular mechanisms, including the organization of the myocardium sarcomere, megakaryocyte maturation, and platelet shedding. It achieves these functions through its involvement in actin filament disassembly, in cooperation with ADF/cofilin family proteins, and plays a significant role in cell migration, cytokinesis, and the maintenance of epithelial apical cell junctions.

THERAPEUTIC SIGNIFICANCE:
Linked to Periodic fever, immunodeficiency, and thrombocytopenia syndrome, WD repeat-containing protein 1's manipulation offers a promising avenue for therapeutic intervention in this complex immunologic disorder. Its multifaceted role in biological systems makes it an intriguing subject for scientific inquiry and drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.